Overview
Jeff Elton, Ph.D., is chief executive officer of ConcertAI, an AI SaaS solutions company providing research solutions and patient-centric solutions for life sciences innovators and the world’s leading providers per ConcertAI’s leadership page. ConcertAI focuses on accelerating and improving the precision of retrospective and prospective clinical studies using provider EMRs, laboratory information systems, and PACS as the source for all study data.
ConcertAI is a long-term partner with the American Society of Clinical Oncology and its CancerLinQ program, the U.S. FDA, NCI Health Equity initiatives, and almost 100 healthcare providers across the U.S. per the cited leadership biography.
Role and company
As CEO, Elton leads ConcertAI’s portfolio spanning life-sciences SaaS, clinicogenomic data services, and provider-facing oncology analytics. ConcertAI launched Accelerated Clinical Trials (ACT), an enterprise agentic AI platform for clinical trial automation, in February 2026 per company news materials.
Elton’s leadership page describes ConcertAI as focused on embedding AI directly into clinical trial design, feasibility, site selection, and commercial patient-journey workflows as enterprise software tied to multi-year pharma partnerships.
Background and career context
Prior to ConcertAI, Elton was Managing Director at Accenture Strategy/Patient Health; Global Chief Operating Officer and SVP Strategy at Novartis Institutes of BioMedical Research; and partner at McKinsey & Company per his ConcertAI leadership biography. He is a founding board member and senior advisor to several early-stage companies and a board member of the Massachusetts Biotechnology Council.
Elton holds a Ph.D. and M.B.A. from The University of Chicago and co-authored Healthcare Disrupted (Wiley, 2016) per the leadership page.
Company-building or leadership context
Elton has led ConcertAI since its 2017 founding in Cambridge, Massachusetts, building oncology real-world data and AI capabilities through partnerships with health systems and ASCO CancerLinQ. His prior Novartis and McKinsey experience shaped ConcertAI’s enterprise sales motion toward pharma R&D and health-system research collaborations rather than consumer health products.
ConcertAI’s leadership page lists Elton as CEO — the primary official source for his current operating title reviewed July 10, 2026.
Public milestones
2017: ConcertAI founded in Cambridge, Massachusetts. February 2, 2026: ConcertAI launched Accelerated Clinical Trials (ACT) enterprise agentic AI platform for clinical trial automation per company news. ConcertAI maintains partnerships with ASCO CancerLinQ, FDA, NCI Health Equity initiatives, and ~100 healthcare providers per leadership biography.
Elton is named CEO on concertai.com/leadership reviewed in this profile.
Why their work matters
ConcertAI under Elton represents applied agentic AI in oncology research operations — automating trial feasibility and site selection using real-world data rather than standalone chat interfaces. CancerLinQ partnership gives ConcertAI structured oncology data scale few startups replicate without decade-long health-system relationship building.
For healthcare AI readers, ConcertAI is life-sciences and provider analytics AI — distinct from bedside clinical workflow tools but central to how AI shapes drug development timelines.
Sources and references
Primary sourcing: ConcertAI leadership page Jeff Elton biography, reviewed July 10, 2026.
- ConcertAI — Leadership (concertai.com)
Prior roles and education from ConcertAI leadership biography only. ACT launch from ConcertAI news February 2026.
ConcertAI leadership biography notes Elton co-authored Healthcare Disrupted (Wiley, 2016) and maintains Massachusetts Biotechnology Council board membership — thought-leadership visibility that supports enterprise pharma and provider research partnerships beyond software feature comparisons. CancerLinQ and FDA collaborations cited on the leadership page give ConcertAI longitudinal oncology data scale under Elton’s executive tenure.
ConcertAI leadership page states the company is a long-term partner with ASCO CancerLinQ, U.S. FDA, NCI Health Equity initiatives, and almost 100 healthcare providers across the U.S. — partnership density Elton’s CEO role cultivated for real-world evidence and agentic clinical trial automation products including ACT launched February 2026.